Sep 28, 2026 · 30 min · 10 segments
In this episode of Inside Pharma Leadership, I sit down with Brian Russon, CEO of PhenoBiome, to explore the growing role of the microbiome in health and precision nutrition. We discuss the challenges…
Brian RussonGuest
Keith WillisHost
What is navigating through the noise? I would say that's probably the largest challenge.

There's a lot of influence in the market around gut health and what we're doing in gut health.

There's a lot of non-clinically validated products that are in the market around gut health.

Great anecdotal data, great placebo effect data, less clinical validity data and so i would say that the the largest challenge that we're facing is how do we how do we migrate out of that i heard about gut health and now i want to be involved to moving into a really strong and robust product that has clinical validity

okay so it sounds like you're going to go down the road of clinical trials those type of things

Yeah, clinical trials, education, that clinical validity of both the science and then the application of that science in trial.

As we look at either direct partnerships or direct corollary product effects that have indication-specific activity, then that will move down the FDA path with those products.

So then basically, I would assume you'll think about direct-to-consumer, or will you look at access as far as managed markets, managed care, being able to reimburse those type of things?
prefer to be behind
we are a science led

So we have a number of distributors in the direct to consumer spaces that sell microbiome products or sell other products in the market that are looking for a clinically validated microbiome product to incorporate alongside of
their existing product lines.

What is navigating through the noise? I would say that's probably the largest challenge.

There's a lot of influence in the market around gut health and what we're doing in gut health.

There's a lot of non-clinically validated products that are in the market around gut health.

Great anecdotal data, great placebo effect data, less clinical validity data and so i would say that the the largest challenge that we're facing is how do we how do we migrate out of that i heard about gut health and now i want to be involved to moving into a really strong and robust product that has clinical validity

okay so it sounds like you're going to go down the road of clinical trials those type of things

Yeah, clinical trials, education, that clinical validity of both the science and then the application of that science in trial.

As we look at either direct partnerships or direct corollary product effects that have indication-specific activity, then that will move down the FDA path with those products.

So then basically, I would assume you'll think about direct-to-consumer, or will you look at access as far as managed markets, managed care, being able to reimburse those type of things?
prefer to be behind
we are a science led

So we have a number of distributors in the direct to consumer spaces that sell microbiome products or sell other products in the market that are looking for a clinically validated microbiome product to incorporate alongside of
their existing product lines.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.